Palau is pausing the use of the Johnson & Johnson/Janssen Covid-19 vaccine, and will wait further guidance from the United States. 

Gaafar Uherbelau,  Ministry of Health’s Emergency Operation Center’s (EOC) Deputy Incident Commander said the decision was base on the recommendation by the US Food and Drug Administration and US Centers for Disease Control and Prevention.

 The US agencies earlier made the recommendation based on the “rare and severe” cases of blood clot reported.

There had been 6.8 million people who has been vaccinated using J&J vaccine.  

As of April 12, more than 6.8 million doses of the Johnson & Johnson (Janssen) vaccine have been administered in the U.S, according to statement from CDC and FDA statement.

“Right now, these adverse events appear to be extremely rare. COVID-19 vaccine safety is a top priority for the federal government, and we take all reports of health problems following COVID-19 vaccination very seriously,” the statement said.

There were  six reported in the  U.S.  of blood clot in individuals after receiving the J&J vaccine. 

“In these cases, a type of blood clot called cerebral venous sinus thrombosis (CVST) was seen in combination with low levels of blood platelets (thrombocytopenia).”

The CDC and FDA said all  six cases occurred among women between the ages of 18 and 48, and symptoms occurred 6 to 13 days after vaccination.

Palau has started administering the Johnson &Johnson vaccine to residents here especially in outlaying states, but no severe side effects have been reported.

“Yes we will pause, Johnson & Johnson while we await further guidance,” Uherbelau said.

According to the Minister of Health’s COVID-19 Situation Report,  8,224 total persons in Palau  were  fully vaccinated; or 46 percent  of population fully vaccinated. 

Vaccination using the Moderna will continue on April 19, opening the program to  all eligible residents  adults.


On April 8, Palau received an additional 8,400 doses of Moderna vaccine. 

Leave a comment

Your email address will not be published. Required fields are marked *